반응식
[NH2:1][CH2:2][CH2:3][CH2:4][N:5]1[CH2:9][CH2:8][CH2:7][C:6]1=[O:10].[CH2:11]([O:13][C:14]([C:16]1[C:17](=[O:39])[C:18]2[CH:23]=[N:22][C:21](S(C)(=O)=O)=[N:20][C:19]=2[N:28]([C:30]2[CH:31]=[C:32]3[C:36](=[CH:37][CH:38]=2)[CH2:35][CH2:34][CH2:33]3)[CH:29]=1)=[O:15])[CH3:12]>>[CH2:11]([O:13][C:14]([C:16]1[C:17](=[O:39])[C:18]2[CH:23]=[N:22][C:21]([NH:1][CH2:2][CH2:3][CH2:4][N:5]3[CH2:9][CH2:8][CH2:7][C:6]3=[O:10])=[N:20][C:19]=2[N:28]([C:30]2[CH:31]=[C:32]3[C:36](=[CH:37][CH:38]=2)[CH2:35][CH2:34][CH2:33]3)[CH:29]=1)=[O:15])[CH3:12]참가 물질
3
반응물 2
생성물 1
실험 절차
Using the procedure outlined in Example 1 Step F, the title compound was prepared from 1-(3-amino-propyl)-pyrrolidin-2-one and 8-indan-5-yl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 1(Step E) 25 mg, 0.052 mmol). 17 mg of 8-Indan-5-yl-5-oxo-2-[3-(2-oxo-pyrrolidin-1-yl)-propylamino]-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ (ppm): 9.25 (s, 1H), 8.46 (s, 1H), 7.33 (d, J=7.7 Hz, 1H), 7.23 (s, 1H), 7.16 (d, J=7.7 Hz, 1H), 6.26 (br, 1H), 4.37 (q, J=7.3 Hz, 2H), 3.36 (m, 2H), 3.27 (m, 2H), 3.00 (m, 4H), 2.37 (t, J=7.9 Hz, 2H), 2.18 (m, 2H), 2.00 (m, 2H), 1.60 (m, 4H), 1.38 (t, J=7.3 Hz).
출처 및 근거
- ORD 기록
- ord-7103322ccabc4c2ba5b9486553491181
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07728003B2
연결된 노트
불러오는 중…